ABSTRACT: Lipid droplets (LDs) are distinct and dynamic organelles that affect the health of cells and organs. Much progress has been made in understanding how these structures are formed, how they interact with other cellular organelles, how they are used for storage of triacylglycerol in adipose tissue, and how they regulate lipolysis. Our understanding of the biology of LDs in the heart and vascular tissue is relatively primitive in comparison with LDs in adipose tissue and liver. The National Heart, Lung, and Blood Institute convened a working group to discuss how LDs affect cardiovascular diseases. The goal of the working group was to examine the current state of knowledge on the cell biology of LDs, including current methods to study them in cells and organs and reflect on how LDs influence the development and progression of cardiovascular diseases. This review summarizes the working group discussion and recommendations on research areas ripe for future investigation that will likely improve our understanding of atherosclerosis and heart function. L ipid droplets (LDs) are dynamic organelles that store neutral lipids for later use during energy deficit. Imbalance of LD function has been implicated in various human diseases. Overabundant and enlarged LDs are the hallmarks of obesity, type 2 diabetes mellitus, liver steatosis, atherosclerosis, cardiac steatosis, and cardiomyopathy. 1 Conversely, failure to develop or maintain adipose tissue in lipodystrophies, a group of heterogeneous disorders characterized by varying degrees of body fat loss or redistribution of fat, leads to insulin resistance and other metabolic complications. Several genetic causes of the familial forms of lipodystrophy are linked to LD biology, and a number of relatively rare forms of cardiomyopathy are characterized by excess LDs.
ABSTRACT: Lipid droplets (LDs) are distinct and dynamic organelles that affect the health of cells and organs. Much progress has been made in understanding how these structures are formed, how they interact with other cellular organelles, how they are used for storage of triacylglycerol in adipose tissue, and how they regulate lipolysis. Our understanding of the biology of LDs in the heart and vascular tissue is relatively primitive in comparison with LDs in adipose tissue and liver. The National Heart, Lung, and Blood Institute convened a working group to discuss how LDs affect cardiovascular diseases. The goal of the working group was to examine the current state of knowledge on the cell biology of LDs, including current methods to study them in cells and organs and reflect on how LDs influence the development and progression of cardiovascular diseases. This review summarizes the working group discussion and recommendations on research areas ripe for future investigation that will likely improve our understanding of atherosclerosis and heart function.
L
ipid droplets (LDs) are dynamic organelles that store neutral lipids for later use during energy deficit. Imbalance of LD function has been implicated in various human diseases. Overabundant and enlarged LDs are the hallmarks of obesity, type 2 diabetes mellitus, liver steatosis, atherosclerosis, cardiac steatosis, and cardiomyopathy. 1 Conversely, failure to develop or maintain adipose tissue in lipodystrophies, a group of heterogeneous disorders characterized by varying degrees of body fat loss or redistribution of fat, leads to insulin resistance and other metabolic complications. Several genetic causes of the familial forms of lipodystrophy are linked to LD biology, and a number of relatively rare forms of cardiomyopathy are characterized by excess LDs.
Although major advances have been made in the past 20 years to characterize LDs and their relationship to adipose and liver biology, less investigation has focused on LDs and cardiovascular disease (CVD) (Figure) . We now understand that LDs exhibit a dual nature in cardiovascular health. In some situations, the storage of lipid within droplets is a marker for lipid overload and reduced cardiac function. Dysfunction in storage and turnover of endogenous triglyceride within the LD of the cardiomyocyte is related to impaired transcriptional regulation of metabolic gene expression in failing hearts and reduced mitochondrial generation of energy to support, the energy demands of the contractile apparatus. [2] [3] [4] [5] [6] In other circumstances, LDs may prevent lipid toxicity by sequestering toxic lipid species such as cholesterol, ceramides, and sn-1,2-diacylglycerols. 7 Another example is the accumulation of cholesterol esters in the LDs of macrophages (foam cells) in arteries, an important step in atherosclerosis development. Within the atherosclerotic plaque, LDs can serve as a safe reservoir to store cholesterol esters until they can be removed from macrophages. However, little is known regarding the protein compositions of LDs in foam cells and how formation and mobilization of LDs are regulated in the context of atherosclerosis.
To evaluate the state of the field in LD research, identify the gap areas in cardiovascular research, and foster collaborations among researchers in the scientific community, the National Heart, Lung, and Blood Institute convened a working group in May 2017 to discuss the emerging importance of studying the role of LDs in CVD. The working group comprised 12 experts from diverse backgrounds in diabetes mellitus, liver diseases, cardiovascular research, proteomics, nuclear magnetic resonance, and cell and systems biology. In this report, we provide a summary of the workshop presentations, discussion, and recommendations for future research on the role of LDs in CVD with 3 objectives: (1) to summarize the current information available on the roles of LDs in heart function and vascular disease, (2) to discuss the state-of-the-art technologies in the field that may be suitable for further development, and (3) to identify gaps in knowledge and opportunities for high-impact research in the future.
CURRENT STATE OF KNOWLEDGE
What Are the Function, Composition, and Structure of LDs?
LDs are cytosolic organelles composed of a neutral lipid core (which may contain triacylglycerols [TAGs], cholesteryl esters [CEs] , retinyl esters, ether lipids, and other neutral lipids) surrounded by a phospholipid monolayer with many surface proteins. LDs were traditionally considered inert organelles whose sole purpose was to store lipids. This view has been overturned in the past decade, with better understanding of the biogenesis, composition, modification, and regulation of LDs. LDs (which have also been called intracellular lipoproteins)
are now viewed as dynamic organelles with diverse properties and functions across cell types, playing a crucial role in lipid metabolism and energy homeostasis, metabolic gene expression, intracellular lipid and membrane trafficking, viral infection, and inflammatory responses.
Adipocytes are uniquely specialized to store large amounts of lipid in the form of LDs. Nevertheless, other tissues also store lipids, in particular, in times of calorie excess. Exceeding the normal LD storage capacity of adipocytes, as can occur in obesity and lipodystrophy, results in ectopic lipid accumulation in other tissues (including skeletal muscle, liver, pancreatic β-cells), which contributes to insulin resistance, fatty liver, and CVD. Liver, heart, and kidneys also harbor increased LDs during fasting/starvation when levels of nonesterified fatty acids in the circulation rise.
Several proteins and enzymes are associated with LDs, and these proteins synthesize TAGs and phospholipids, and liberate stored lipids. Probably the best studied LD structural proteins are the 5 members of the perilipin (PLIN) family. PLINs regulate the actions of lipases. Under basal conditions, PLINs limit LD hydrolysis and fatty acid release; under stimulated conditions (such as catecholamine treatment), PLIN1 and PLIN5 promote LD hydrolysis to provide fatty acids for processes such as oxidation.
How Is LD Size Regulated?
The regulation of LD size and abundance is critical for metabolic homeostasis. Conditions associated with increased LD size and number (obesity) or inability to form or store LDs (lipodystrophy) are associated with increased risk for dyslipidemia, type 2 diabetes mellitus, atherosclerosis, coronary artery disease, and cardiomyopathy. The enzymes that catalyze TAG synthesis are a determinant of LD formation and have been explored as therapeutic targets to reduce TAG storage. 8 However, complete inhibition of LD synthesis leads to severe disease, because mutations in TAG biosynthetic enzymes 13 In addition to synthesis of the neutral lipid core, the expansion of LDs requires increased phospholipid surface, particularly phosphatidylcholine. During LD expansion, the rate-limiting enzyme in phosphatidylcholine synthesis, CTP: phosphocholine cytidylyltransferase α, senses the phospholipid deficiency on growing LDs and is activated at their surface to maintain the balance between LD core and shell.
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14 Several additional proteins are required to convert nascent to mature LDs, most notably seipin, which appears to act at contact sites between nascent LDs and the endoplasmic reticulum (ER) to promote LD maturation. 15 Generalized lipodystrophy results from deficiency in seipin, and from deficiencies in additional proteins with incompletely understood roles in LD biology, as well (eg, caveolin 1, polymerase I, and transcript release factor). 9, 16 An opposing force to LD TAG synthesis is the mobilization of fatty acids. Fatty acids are important sources of energy and function as signaling mediators and biosynthetic substrates. Because excessive fatty acid mobilization can result in the accumulation of toxic lipid mediators, 17 the core intracellular lipolysis machinery is under tight control. 18, 19 In the heart, this core lipolysis machinery consists of adipose triglyceride lipase (ATGL), the rate-limiting enzyme of triglyceride hydrolysis; ABHD5 (α-beta hydrolase domain-containing 5, also known as CGI-58), an essential coactivator of ATGL; and hormone-sensitive lipase, which mediates hydrolysis of diglycerides generated by ATGL. Mutations of these core proteins are involved in a range of important diseases that include cardiovascular and metabolic disease, and cancer, as well. [20] [21] [22] [23] [24] Intracellular lipolysis is regulated by extracellular signals, such as catecholamines and insulin, in addition to intracellular signal transduction and metabolite levels that together serve to precisely match mobilization of fatty acids with oxidative demand. As such, lipolysis is a highly dynamic process that is spatially compartmentalized and involves rapid (on the order of seconds) trafficking and interactions within the core lipolysis machinery on the surface of LDs. 25 In the heart, these interactions are coordinated by PLIN5, which functions as a dynamic scaffold on the surface of LDs 26 to regulate interactions between ATGL and CGI-58. PLIN5 also has been proposed to play a central role in creating a metabolic synapse between LDs and mitochondria, where fatty acids are oxidized to generate adenosine triphosphate for contraction. 27 PLIN5 in the nucleus has been shown to function as an activator of the PGC-1α (peroxisome proliferator-activated receptorgamma coactivator-1 alpha) transcriptional program to promote mitochondrial biogenesis and oxidative metabolism. 28 Nuclear lipid droplets have been observed in cultured hepatocytes. 29 It is unknown whether the nuclear PLIN5 involved in transcription also coats nuclear LDs. PLIN5 enriches in the nuclear fraction of the fasting mouse heart, but whether PLIN5 regulates gene expression in the heart requires future investigation. It is important to note that the proteins of the core lipolysis machinery can each be targeted by synthetic activators and inhibitors, 27, 30, 31 providing an opportunity for development of new therapeutic approaches for the treatment of CVD.
What Is the Role of LDs in the Heart?
To support the high energy demands of persistent contraction against a pressure load, the heart oxidizes more fat than any other organ. As in some other organs and tissues (with obvious exclusions such as the brain and glycolytic skeletal muscle), long-chain fatty acids (LCFAs) are the primary fuel for oxidative adenosine triphosphate generation for the cardiomyocyte. However, LCFAs also contribute as ligands for nuclear hormone receptors and as substrates for the formation of physiologically active acyl intermediates and synthesis of membrane lipids. On uptake into the heart, fatty acids are coenzyme A (CoA)-esterified via the actions of the acyl-CoA synthetase and fatty acid transport proteins. The fatty acyl-CoAs are esterified onto a glycerol backbone and incorporated into LDs as TAG for subsequent hydrolysis by lipases to supply fatty acids for mitochondrial oxidation and also as ligands for peroxisome proliferator-activated receptor (PPAR) α. 6, 32 Incorporation of fatty acids into the neutral lipid pool within LDs and their controlled release from LDs protects the heart from excess concentrations of acyl intermediates, which can disrupt signaling pathways and lead to tissue dysfunction or injury, known as lipotoxicity.
Perilipins regulate the actions of lipases to either limit the hydrolysis of TAG under basal conditions or to promote such action under stimulated conditions, such as catecholamine treatment. In the heart, most attention has focused on PLIN5, which is preferentially expressed in tissues with high oxidative capacity. Studies in humans have suggested that reduced PLIN5 expression correlates with impaired cardiac function following myocardial infarction 33 and that failing hearts have reduced PLIN5 RNA expression in comparison with donor hearts. 34 In mice, constitutive, whole-body gene knockout of Plin5 results in the absence of myocardial lipid droplets, and in age-related cardiomyopathy, as well, that is prevented by antioxidant therapy 35 and in increased infarct size and cardiac dysfunction following ischemia reperfusion. 36 Conversely, heart-specific overexpression of PLIN5 has been associated with cardiac steatosis and cardiac hypertrophy. 37, 38 Thus, having the right amount of PLIN5 in the heart at the right time likely is important for the maintenance of normal heart structure and function. Future work in genetically engineered mouse models is needed to address the mechanisms and downstream pathways that underlie the effects of PLIN5 dose on cardiac lipid metabolism, histology, and function.
In hyperlipidemic states, LDs accumulate in the heart (ie, cardiac steatosis), at least in part, because of the delivery of surplus metabolic substrates to the heart, which expresses the biochemical enzymes and possesses the cellular machinery for LD formation. Accumulation of lipids in myocardial LDs is associated with heart failure in obesity and diabetes mellitus, diseases characterized by hyperlipidemia. 39 Studies using localized 1 H magnetic resonance spectroscopy to detect cardiac steatosis in patients with impaired glucose tolerance or type 2 diabetes mellitus indicate that an increase in the lipid content of the myocardium can precede the development of heart failure. 40 In experimental rodent models, studies combining cardiac-tagging MRI and proton magnetic resonance spectroscopy demonstrate that even a short-term high-fat diet expands the pool of LDs and induces early impairment of contractility. 41 The hearts of chronically diabetic mice are characterized by very high TAG content and turnover rates, associated with chronically high PPARα expression and activation. 2, 3 Elevated TAG turnover results from PPARα activation that is known to induce target gene expression for LCFA uptake, β-oxidation enzymes, and both TAG synthesis and lipolysis. Under such conditions, the endogenous TAG pool of the diabetic heart contributes to the already elevated mitochondrial β-oxidation of LCFAs within the mitochondria, oxidative stress, and formation of ceramides. 42 To determine whether lipid overload alone can cause heart dysfunction, several laboratories created genetically modified mice with enhanced cardiomyocyte lipid uptake or reduced cardiac fatty acid metabolism. [43] [44] [45] In these models of cardiac lipotoxicity, imbalance between lipid import and metabolism leads to lipid accumulation, cardiomyopathy, and, in some cases, sudden death. Thus, although metabolic channeling of excess fatty acids to intracellular TAG stores may serve an initial cytoprotective role by sequestering excess fatty acids away from mitochondria, ER, lysosomes, and other organelles, 4, 46, 47 the capacity for physiological storage of lipids in the heart is limited. In the setting of prolonged lipid excess, storage capacity is overwhelmed and TAG hydrolysis exceeds synthesis. Lipotoxicity ensues, initially manifesting as organelle dysfunction, and ultimately leading to cell death and tissue damage. [48] [49] [50] In contrast to these examples of lipid-induced toxicity, greater numbers or increased size of LDs, occurring during prolonged fasting or via overexpression of diacylglycerol acyltransferase-1, do not cause toxicity, 51 likely because fatty acids esterified as TAGs and stored in LDs are protected from enzymatic conversion to potentially toxic metabolites. In some animal models, enhanced sequestration of fatty acids in LDs improves cardiac function in the setting of lipid overload, whereas decreased LD capacity promotes oxidative stress and functional decline. In other models, such as mice with germline loss-of-function of ATGL, marked cardiac steatosis causes heart failure and premature death. 52 Experiments in whole-body, constitutive ATGL knockout mice suggested that lipolytic release from LDs of lipid ligand(s) for PPARα is required for activation of target genes necessary for maintenance of normal mitochondrial substrate oxidation and respiration. 53 Thus, it appears that cardiac lipid storage and hydrolysis may be physiological or pathological. This parallels lipid storage in skeletal muscle, in which excess LD accumulation is associated with insulin resistance in obese and sedentary individuals, but may also be associated with improved muscle function and greater insulin sensitivity in other cases (the latter being known as the athlete's paradox). 53a These genetic models have served as platforms for discovery of the pathophysiology of lipid overload in the heart, providing novel insights into the effects of different diet compositions, and the crosstalk between sex hormones and lipid metabolism, as well. 2, 54 In addition, a signature of metabolic and signaling pathways mediated by lipid overload in vivo has emerged. In the lipidoverloaded heart, palmitate serves as substrate for de novo synthesis of ceramides, which have been shown to be cardiotoxic. 55 As has been demonstrated in cell culture models of lipotoxicity, lipid overload incites oxidative and ER stress in the heart. 2, 53, 56 Genetic screens have also uncovered novel roles for several noncoding RNAs in the regulation of lipotoxicity, 57, 58 although the contributions of these RNAs to lipotoxicity in vivo remain to be determined. Despite recent advances, the endogenous mechanisms that determine the transition between adaptive lipid storage and lipotoxicity are not well understood. This represents an important area for investigation with the potential to identify new therapeutic targets.
How Do LDs Interact With Membrane and Intracellular Signaling Pathways?
Nutrient sensing plays an important role in how cells remodel LD metabolism to adapt to energy transitions. 59, 60 At the plasma membrane, the fatty acid receptor CD36 transduces intracellular signals that function to regulate nutrient metabolism. In cardiomyocytes, CD36 mediates both fatty acid activation of 5ʹ-adenosine monophosphate-activated protein kinase and inhibition of the insulin receptor. It also influences cytosolic calcium transients by regulating inositol trisphosphate generation and store-operated calcium entry, 61 ,62 a pathway that can be activated by fatty acids. CD36 signaling controls mobilization of LDs, cellular production of eicosanoids, and the secretion of neurotransmitters (serotonin) and enteropeptides (cholecystokinin, secretin) that influence cellular fat processing. 63 In the heart, CD36 might help link membrane signal transduction to LD metabolism by coordinating several events that could influence LD trafficking and composition. Membrane-signaling events could include the initiation of calcium transients, activation of phospholipase for phospholipid remodeling, and phosphorylation of proteins linked to 5ʹ-adenosine monophosphate-activated protein kinase activation and intracellular TAG breakdown. 64, 65 It is interesting to note that the LD proteome includes a substantial number of proteins that function in cell signaling, membrane traffic, and interaction between organelles. 66, 67 More focus on the mechanisms that coordinate plasma membrane signaling with LD trafficking, composition, and turnover is needed. In this context, a better understanding of the role of calcium dynamics in coordinating metabolic and functional adaptation of the heart is important.
Ectopic lipid deposition also plays a major role in the pathogenesis of hepatic insulin resistance and type 2 diabetes mellitus. 12, 68 Nonalcoholic fatty liver disease affects 1 in 3 Americans, is a major predisposing factor for nonalcoholic steatohepatitis and hepatocellular cancer, and is an independent risk factor for CVD. Understanding the cellular and molecular mechanisms by which ectopic lipid promotes insulin resistance in liver, and identifying the key lipid mediators in this process, is therefore of great interest. In a model of high-fat feeding nonalcoholic fatty liver disease, sn-1,2-diacylglycerols have been shown to trigger hepatic insulin resistance through translocation/activation of protein kinase C-ε, resulting in phosphorylation of insulin receptor Thr 1160 (mouse Thr
1150
) and inhibition of insulin receptor kinase activity. 69 However, it is important to note that alterations in the cellular compartmentation of sn-1,2-diacylglycerol play an important role in lipid-induced hepatic insulin resistance as reflected by the increase in hepatic diacylglycerol content in LDs in CGI-58 antisense oligonucleotide-treated rats despite the lack of protein kinase C-ε translocation/activation and hepatic insulin resistance. 70 This hypothesis can also explain the lack of association of hepatic steatosis and hepatic insulin resistance in other conditions of increased lipid storage in LDs (eg, apolipoprotein B deficiency, mitochondrial trifunctional protein deficiency, etc). In addition, alterations in hepatic acetyl-CoA, an allosteric activator of pyruvate carboxylase, have been shown to mediate insulin suppression of hepatic gluconeogenesis and promote increased rates of hepatic gluconeogenesis in animal models of poorly controlled type 1 and 2 diabetes mellitus. 71 Other studies have implicated ceramides as intracellular lipids that may also block insulin-signaling pathways. 72 Thus, the regulation of cytosolic-signaling lipids affects insulin actions and hepatic gluconeogenesis independent of hepatocellular insulin signaling.
What Is Known About the Structure and Function of Cholesterol-Enriched LDs Within Atherosclerotic Plaques?
Because free cholesterol cannot accumulate safely in cells, as its content increases, progressively more is esterified to CE and stored. Thus, macrophages in atherosclerotic plaques frequently become foamy in appearance because of the accumulation of CE that eventually concentrates in LDs. CE formation is mediated by the acyl-CoA cholesterol acyltransferase enzymes. 73 Classic studies by Brown and Goldstein showed that, like TAGrich LDs in other tissues, there is a dynamic turnover of CE in macrophage foam cells. 74 Although there are candidate neutral CE hydrolases, controversy persists over which enzyme hydrolyzes CE in different species. 75 Macrophage formation of LDs appears to be cytoprotective. Deletion of ACAT1 from macrophages in lowdensity lipoprotein receptor-deficient mice prone to develop atherosclerosis results in increased macrophage lipotoxicity and atherogenic load. 7 Conversely, limiting cholesterol accumulation, for instance, by reducing the absorption of dietary cholesterol in ACAT2-deficient mice, protects from atherogenesis. 76 In addition, oxidized CEs have been found to accumulate in human atherosclerotic plaques. 77 Over 50 unique lipid products derived from cholesteryl-linoleate alone, accounting for 20% to 90% of the lipid mass in plaques, have been characterized. 77 Recent reports suggest that some oxidized CEs can exert untoward biological activity. 78 TAGs are also found in atherosclerotic plaques from humans and animals, and are very likely to comprise part of the LDs in macrophages as admixtures in a liquid crystalline, isotropic state. 79 In cell culture, the efflux of cholesterol differs from pure CE-LDs versus CE/TAG-LDs, 79 ,80 with higher rates in the latter. LDs are thought to be not only storage containers in macrophage foam cells, but also direct and indirect contributors to the pathology of progressing plaques. 81, 82 Vascular smooth muscle cells can also become foam cells in atherosclerotic plaques. Recent research has shown that these foam cells can become macrophage-like in their phenotype 83, 84 and can comprise in excess of 30% of the cells identified as macrophages with standard immunostaining in human and murine plaques. 85 In vitro, vascular smooth muscle cell transdifferentiation to a macrophage-like state can be accomplished by loading the cells with cholesterol, which accumulates in CE-LDs. 83, 84 It is unknown whether it is the free cholesterol pool or the CE-LD that is integral in the transdifferentiation of vascular smooth muscle cells to macrophage-like cells, and the regulatory process involved is undefined.
What Do We Know About the Cellular Metabolism of LDs?
LDs make dynamic contacts with nearly every other organelle in the cell. 86 These contacts are thought to mediate transfer of lipids (including phospholipids, sterols, and fatty acids) between the different cellular compartments. 87, 88 Contact sites between lipid droplets and other organelles may allow for metabolic channeling, because various steps in lipid anabolic and catabolic pathways may occur in different organelles, including the ER, Golgi, plasma membrane, lysosomes, mitochondria, and peroxisomes. Progress has recently been made in identifying some of the proteins that mediate LD-organelle membrane contacts. 87, 88 For example, FATP1 (fatty acid transport protein 1) and DGAT2 at the ER-LD interface are involved in LD expansion, 89 whereas PLIN5 has been implicated in forming LD-mitochondria contacts and in channeling fatty acids from LDs to mitochondria in liver and skeletal muscle. 90 However, for most LD-organelle contacts, the proteins and lipids involved have not been identified. In addition, in many cases it is unclear what types of lipids are transferred and what the directionality of transfer is at these contact sites. To answer these questions, tools for visualizing lipid trafficking in live cells will be necessary.
Studies to assess TAG storage, and the formation and dissolution of LDs in the heart require sophisticated nuclear magnetic resonance methods and stable isotope kinetics. As discussed in an earlier section, turnover of the TAG pool in cardiomyocytes is intimately linked to expression of PPARα target genes. Stable isotope-based measurements of TAG turnover within cardiomyocytes of the intact, functioning heart have been performed on rat hearts subjected to chronic pressure overload. 5, 6 Measurements from pathologically hypertrophied hearts revealed reduced TAG content and turnover, associated with reduced expression of PPARα target genes. A consequence of the reduction in TAG dynamics is the accumulation of a lipotoxic acyl derivative, the 16-carbon species of ceramide, which is consistent with measurements made in sampled human failing hearts. 6, 91 However, dietary LCFAs can modulate heart TAG content, with monounsaturated oleate (18:1) supporting higher TAG dynamics than saturated palmitate (16:0). 6 Oleate-dependent changes in TAG turnover were associated with either attenuated losses or normalized expression levels of metabolic enzymes induced by PPARα activity.
CONCLUSIONS Summary and Future Directions
Current research is mostly focused on the basic biology of LDs and the elucidation of the roles of LDs in energy storage. Although much emphasis has been placed on understanding how LDs function in adipocytes and hepatocytes, LDs are known to be present in almost every cell type, where they may interact (in a cell typespecific manner) with various proteins to exert broader functions beyond lipid storage. Indeed, it is appreciated that the composition and turnover of lipids in LDs is an active component of metabolic signaling within both cardiomyocytes and endothelial cells, and mediates the cellular response to pathological stress. The National Heart, Lung, and Blood Institute working group concluded that a better understanding of key regulatory pathways and functions of LDs in different cell types may yield mechanistic insights into the pathological processes that lead to ectopic lipid storage, insulin resistance, inflammation, and associated CVD. To guide research in exploring the roles of LDs in CVD, the working group members identified gap areas and recommended research opportunities to investigate the roles of LDs in the pathogenesis of obesity-and metabolic syndromerelated CVD. Some of these gap areas are described below and in Table; a complete list of research opportunities that were identified by the working group can be found online.
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What Are the Function, Composition, and Structure of LDs? One fundamental gap in knowledge is the biological roles of LDs in the cardiovascular system. More research is needed to understand the similarity and differences in function, composition, and structure of LDs in the cardiovascular system in comparison with LDs in adipose tissue and liver. Once we know the key components, regulators, and interactions of LDs in cardiovascular cells and tissues, we will have a better understanding of the physiological and pathological roles of LDs in the cardiovascular system. To address this unmet need, a combination of methods and tools will be needed to analyze LDs in cardiovascular tissues and relevant cell types, including structural information of the enzymes and key players, metabolic flux analysis (mass spectrometry), measurements of the dynamic composition of LDs using proteomics/lipidomics, and new imaging approaches. One critical challenge is the lack of reliable methodologies to identify and quantify intracellular lipids and proteins associated with LDs. Modern techniques in mass spectrometry can provide information about the concentration of abundant lipids and the minor lipid species that may be active in picomolar or nanomolar concentrations. Stable isotope dilution quantitation by mass spectrometry has unsurpassed precision and accuracy in lipid analysis. Lipidomic analysis based on tandem mass spectrometry has emerged as a powerful strategy to reveal changes in the hundreds of neutral lipids and phospholipid species found in LDs. An additional valuable technique is nanoscale secondary ion mass spectrometry that combines imaging of cells or tissues with mass spectrometry, which has been used to study the movement of fatty acids across capillaries and the distribution of cholesterol in the plasma membrane. 92, 93 It is important to validate the initial hits from the discovery study to differentiate contaminants from true LD-associated proteins or lipids. Developing and sharing methodologies and best practices of isolating LDs and establishing a LD protein and lipid databases will be critical to the field.
How Is LD Size Regulated? What Do We Know About the Cellular Metabolism of LDs?
The size of LDs changes in response to physiological stimuli. Understanding how the formation and catabolism of LDs are regulated will shed light on the mechanisms underlying the transition between adaptive lipid storage and lipotoxicity. One major hurdle is the lack of tools to study the dynamics of LDs in vivo in real time. Strategies that have been used to visualize lipid trafficking within cells, including naturally fluorescent lipids, fluorophore-conjugated lipids, and lipid-binding probes (such as proteins, toxins, and antibodies 94 ), have limitations. Naturally fluorescent lipids are not very bright or photostable, whereas labeling lipids with fluorophores tends to alter their physical properties and metabolism. In addition, for many classes of lipids, no specific probes are currently available. Therefore, the development of new probes that minimally disrupt lipid function, and further validation of existing tools, as well, will greatly advance the field. The analysis of intracellular lipolysis will also benefit from the development of chemical and genetic probes for manipulating and monitoring critical temporal and spatial domains. It is important to note that recent work indicates that elements of the core lipolysis pathway are highly tractable targets for chemical/pharmacological manipulation. 27, 95, 96 Because the core lipolysis machinery is highly conserved and exhibits coevolution among regulatory elements, comparative analysis across species is likely to lead to new insights and understanding of this important pathway. [97] [98] [99] What Is the Role of LDs in the Heart? Greater understanding of the biology of LD formation, its relationship with cellular levels of toxic lipid intermediates, and its role in cardiac responses to pathological processes are needed. The questions that are incompletely answered are the following: What controls uptake of lipids into the heart and the targeting of lipids to oxidation versus storage? Do membrane-initiated signaling events influence LD phospholipid remodeling, LD trafficking, or turnover? Are LDs a necessary intermediate for myocardial fatty acid oxidation? How do fatty acids traffic from LDs to mitochondria? Does increased fatty acid oxidation improve or worsen the response to ischemia and increased afterload, and do the effects differ in acute in comparison with chronic situations? The biological pathways leading to both pathological and physiological (protective) LD formation need to be defined. How do LDs in healthy and unhealthy states differ in composition? These LDs likely have different effects on hearts that are stressed with greater afterload and ischemic insults. Finally, how do these 2 types of LDs differ in pathological conditions such as diabetes mellitus, obesity, and underlying cardiac diseases?
How do LDs Interact With Membrane and Intracellular Signaling Pathways?
LDs are important hubs that physically interact with numerous organelles. 87 In addition to LD formation, ER interactions have been implicated in ER stress and quality control during protein synthesis. Furthermore, the interface between LD and mitochondria appears to form a specialized synapse in cardiomyocytes that provides tight control of fuel mobilization and oxidation for adenosine triphosphate production. LDs are also known to associate with peroxisomes, lysosomes, and nuclei in various experimental systems, although the nature of these interactions and their functional significance in the cardiovascular system has not been addressed. A more intense focus on the signaling, metabolite trafficking, and protein-protein interaction between LD and various organelles is critical for uncovering the physiological role of LD and the impact of these processes on CVD. Such analyses will require development and implementation of high-resolution techniques that establish the relationships among organelles, and novel molecular probes that directly assess dynamic nutrient flux and protein interactions in living cells, as well.
What Is Known About the Structure and Function of Cholesterol-Enriched LDs Within Atherosclerotic Plaques?
Although important features of cholesterol-enriched LDs have been discovered, there are opportunities to expand the molecular information about the required proteins/signaling cascades and their regulation. The major enzyme that esterifies cholesterol to CE in CE-LDs is well characterized (acyl-CoA cholesterol acyltransferase), but there is still controversy over the neutral CE hydrolase that mediates the reverse reaction. Moreover, not all lipids in foam cell LDs are likely to be CEs. Atherosclerotic plaques also have a substantial amount of TAG. What is the relative contribution of each neutral lipid class to foam cell formation? What are the roles of other lipids and proteins, found within other LDs, in foam cell LD biology? Does the composition (lipids and proteins) of macrophage foam cell LDs influence the ability to efflux cholesterol or inflammatory activation? The current methods, using neutral lipid staining of tissue or lipid extracts of aortic homogenates, will not adequately address these issues. Higher-resolution imaging and analytical methods applied to specific cell types under conditions of plaque progression and regression are needed. Both macrophages and smooth muscle cells become foam cells, but are the LDs in these cells different?
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